Cytokinetics EVP sells 3,500 shares after option
CYTOKINETICS’ EVP of R&D exercised stock options and sold 3,500 shares under a Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sale transaction in the company’s stock. On September 22, 2026, he exercised a non-qualified stock option for 3,500 shares of common stock at an exercise price of $7.80 per share and acquired the corresponding common shares directly. The filing states that these transactions were made pursuant to a Rule 10b5-1 trading plan. After the option exercise, he held 23,386 shares of common stock directly as reported in the derivative section, and he then sold 3,500 shares of common stock at $68.29 per share on the same date.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,500 shares ($212K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Malik Fady Ibraham
Role
EVP Research & Development
Sold
3,500 shs ($239K)
Approx. gross sale proceeds
$239K
Approx. exercise cost
$27K
Approx. pre-tax spread
$212K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 3,500 | $68.29 | $239K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 23,386 contracts (Direct);
Common Stock — 153,902 shares (Direct)
Key Figures
Shares sold: 3,500 shares
Sale price: $68.29 per share
Options exercised: 3,500 shares
+4 more
7 metrics
Shares sold
3,500 shares
Common stock sale on September 22, 2026
Sale price
$68.29 per share
Common stock sale of 3,500 shares on September 22, 2026
Options exercised
3,500 shares
Non-qualified stock option exercise on September 22, 2026
Option exercise price
$7.80 per share
Non-qualified stock option covering 3,500 shares
Shares held after option exercise
23,386 shares
Directly held common shares after the derivative transaction
Option expiration date
February 27, 2028
Expiration of the non-qualified stock option exercised
Option grant exercise date
March 27, 2018
Exercise/vesting reference date for the non-qualified stock option
Key Terms
Non-Qualified Stock Option, derivative security, Rule 10b5-1 trading plan
3 terms
Non-Qualified Stock Option financial
"He exercised a Non-Qualified Stock Option (Right to Buy) covering 3,500 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
derivative security financial
"Exercise or conversion of derivative security related to common stock"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Rule 10b5-1 trading plan regulatory
"The filing affirms the transactions were made pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTK’s EVP of R&D report on this Form 4?
He exercised options for 3,500 shares of CYTOKINETICS common stock at $7.80 per share and sold 3,500 shares of common stock at $68.29 per share on September 22, 2026, as part of an option exercise-and-sale sequence.
At what price were the CYTK stock options exercised by the EVP of R&D?
He exercised a Non-Qualified Stock Option covering 3,500 shares of CYTOKINETICS common stock at an exercise price of $7.80 per share, with the option originally granted on March 27, 2018 and expiring February 27, 2028.
Were the CYTK insider transactions made under a Rule 10b5-1 trading plan?
Yes. The filing affirms that the reported transactions were made pursuant to a Rule 10b5-1 trading plan, indicating they were executed under a pre-established trading arrangement.
What type of derivative security did the CYTK executive exercise?
He exercised a Non-Qualified Stock Option (Right to Buy) relating to 3,500 underlying shares of CYTOKINETICS common stock, at an exercise price of $7.80 per share, with the option expiring on February 27, 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
